Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 172

Sort by

Sort Order Select

Journal Articles

Education about Transplant-Based Therapies in Sickle Cell Disease: Removing Barriers with Newer Technologies

Abarna Anandaraj, Bethany Schowengerdt, Sidharth Sharma, Rae Blaylark, John E Wagner, Ashish O. Gupta

Blood (2024) 144 (Supplement 1): 7958.

https://doi.org/10.1182/blood-2024-209183

Published: 2024

Journal Articles

TCRα/β Depleted Mobilized Pbscs without Calcineurin Inhibitors in Patients with Fanconi Anemia

Margaret L. MacMillan, Qing Cao, Martin Felices, Megan Larson, David McKenna, Meera Srikanthan, John E Wagner

Blood (2024) 144 (Supplement 1): 3490.

https://doi.org/10.1182/blood-2024-205404

Published: 2024

Journal Articles

In Vivo Correction of a Genetically Humanized Fanconi Anemia Mouse Bone Marrow Failure Model Using Digital Editing Technologies

Branden S Moriarity, Beau R Webber, Colette B Rogers, John E Wagner, Joseph J Peterson, Cassandra Butterbaugh, Paige Carlson

Blood (2024) 144 (Supplement 1): 7461.

https://doi.org/10.1182/blood-2024-210783

Published: 2024

Journal Articles

Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group a]: Updated Results from Global RP-L102 Clinical Trials

Blood (2024) 144 (Supplement 1): 7463.

https://doi.org/10.1182/blood-2024-194638

Published: 2024

Journal Articles

Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate–conditioned Fanconi anemia mice

Blood (2024) 143 (21): 2201–2216.

https://doi.org/10.1182/blood.2023023549

Published: 2024

Includes: Supplemental data

Journal Articles

Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo

Blood (2023) 141 (11): 1337–1352.

https://doi.org/10.1182/blood.2022018440

Published: 2023

Includes: Supplemental data

Journal Articles

Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials

Blood (2022) 140 (Supplement 1): 10646–10647.

https://doi.org/10.1182/blood-2022-168342

Published: 2022

Journal Articles

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Blood (2022) 140 (Supplement 1): 282–283.

https://doi.org/10.1182/blood-2022-165782

Published: 2022

Journal Articles

Phase II Study Optimizing Engraftment in Radiation-Sparing Myeloablative Umbilical Cord Blood Transplant for Hematologic Malignancies in Infants

Alex Hoover, John E. Wagner, Michael R. Verneris, Christen L. Ebens

Blood (2022) 140 (Supplement 1): 4714–4715.

https://doi.org/10.1182/blood-2022-159854

Published: 2022

Journal Articles

A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice

Asim Saha, Sharon Hyzy, Tahirih Lamothe, Katelyn Hammond, Nicholas Clark, Leanne Lanieri, Prashant Bhattarai, Rahul Palchaudhuri, Geoffrey O. Gillard, Jennifer Proctor, Megan J. Riddle, Angela Panoskaltsis-Mortari, Margaret L. MacMillan, John E. Wagner, Hans-Peter Kiem, Lisa M. Olson, Bruce R. Blazar

Blood (2022) 139 (11): 1743–1759.

https://doi.org/10.1182/blood.2021012366

Published: 2022

Includes: Supplemental data

Journal Articles

Gene Therapy for Fanconi Anemia [Group A]: Interim Results of RP-L102 Clinical Trials

Blood (2021) 138 (Supplement 1): 3968.

https://doi.org/10.1182/blood-2021-147071

Published: 2021

Journal Articles

Single Agent CD45-Targeted Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model

Sharon L. Hyzy, MS, Jennifer L Proctor, BS, Geoff O Gillard, PhD, Katelyn J. Hammond, BS, Ganapathy N. Sarma, PhD, Asim Saha, PhD, Nicholas Clark, PhD, Anjali Bhat, MS, Tahirih L Lamothe, BS, Rahul Palchaudhuri, PhD, Bradley R Pearse, PhD, Charlotte F McDonagh, PhD, Hans-Peter Kiem, MDPhD, John E Wagner, MD, Bruce R. Blazar, MD, Anthony E Boitano, PhD, Michael P Cooke, PhD, John C. Davis, Jr., MD MPH, MS

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-140489

Published: 2020

Journal Articles

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan G Holtan, MD, Claudio G. Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-136479

Published: 2020

Journal Articles

Gene Therapy for Fanconi Anemia, Complementation Group a: Updated Results from Ongoing Global Clinical Studies of RP-L102

Agnieszka Czechowicz, MDPhD, Rajni Agarwal, MD, Julián Sevilla, MD PhD, Paula Río, PhD, Susana Navarro, PhD, Brian C Beard, PhD, Kenneth M Law, PhD, Grace Choi, BS, Miriam Zeini, PhD, Eileen Nicoletti, MD, John E Wagner, MD, Claire Booth, MBBS, PhD MSc, Jonathan D Schwartz, MD, Juan A Bueren, PhD, Maria Grazia Roncarolo, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-137106

Published: 2020

Journal Articles

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

Ruta Brazauskas, Graziana M. Scigliuolo, Hai-Lin Wang, Barbara Cappelli, Annalisa Ruggeri, Courtney D. Fitzhugh, Jane S. Hankins, Julie Kanter, Joerg J. Meerpohl, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, Mark C. Walters, John E. Wagner, John F. Tisdale, Eliane Gluckman, Mary Eapen

Blood (2020) 136 (5): 623–626.

https://doi.org/10.1182/blood.2020005687

Published: 2020

Includes: Supplemental data

Journal Articles

Romiplostim Improves Platelet Recovery after UCB Transplant

Georgios E. Christakopoulos, MD, Todd E. DeFor, MS, Stefanie M Hage, RN, John E. Wagner, MD, Michael A. Linden, MD PhD, Claudio G Brunstein, MD PhD, Nelli Bejanyan, MD, Michael R Verneris, MD, Angela R. Smith, MD MS

Blood (2019) 134 (Supplement_1): 1979.

https://doi.org/10.1182/blood-2019-125424

Published: 2019

Journal Articles

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Grigori Okoev, MD PhD, Daniel J. Weisdorf, MD, John E. Wagner, MD, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MDPhDMPH, Najla H El Jurdi, MD, Shernan Holtan, MD, Claudio G Brunstein, MD PhD, Brian C. Betts, MD, Takuto Takahashi, MD, Veronika Bachanova, MD PhD, Erica D. Warlick, MD, Armin Rashidi, MD PhD, Mukta Arora, MD

Blood (2019) 134 (Supplement_1): 2009.

https://doi.org/10.1182/blood-2019-123421

Published: 2019

Journal Articles

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Heather Stefanski, MD PhD, Claudio G Brunstein, MD PhD, David H. McKenna, MD, Darin Sumstad, MLS, Jeffrey S. Miller, MD, Bruce R. Blazar, MD, Todd E. DeFor, MS, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Glen D. Raffel, MD PhD, John C. Davis, Jr., MD MPH, MS, John E. Wagner, MD

Blood (2019) 134 (Supplement_1): 804.

https://doi.org/10.1182/blood-2019-122329

Published: 2019

Journal Articles

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Blood (2018) 132 (Supplement 1): 71.

https://doi.org/10.1182/blood-2018-99-113564

Published: 2018

Journal Articles

Validation of Minnesota Acute GVHD Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All GVHD Is Created Equal

Margaret L. MacMillan, MD, Shernan G. Holtan, MD, Armin Rashidi, MD PhD, Todd E. DeFor, MS, Claudio G Brunstein, MD PhD, John E. Wagner, MD, Bruce R. Blazar, MD, Daniel J. Weisdorf, MD

Blood (2018) 132 (Supplement 1): 67.

https://doi.org/10.1182/blood-2018-99-113085

Published: 2018

NARROW

Education about Transplant-Based Therapies in Sickle Cell Disease: Removing Barriers with Newer Technologies

TCRα/β Depleted Mobilized Pbscs without Calcineurin Inhibitors in Patients with Fanconi Anemia

In Vivo Correction of a Genetically Humanized Fanconi Anemia Mouse Bone Marrow Failure Model Using Digital Editing Technologies

Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group a]: Updated Results from Global RP-L102 Clinical Trials

Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate–conditioned Fanconi anemia mice

Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo

Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Phase II Study Optimizing Engraftment in Radiation-Sparing Myeloablative Umbilical Cord Blood Transplant for Hematologic Malignancies in Infants

A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice

Gene Therapy for Fanconi Anemia [Group A]: Interim Results of RP-L102 Clinical Trials

Single Agent CD45-Targeted Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model

Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Gene Therapy for Fanconi Anemia, Complementation Group a: Updated Results from Ongoing Global Clinical Studies of RP-L102

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

Romiplostim Improves Platelet Recovery after UCB Transplant

Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Validation of Minnesota Acute GVHD Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All GVHD Is Created Equal

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only